CTLA4 and colorectal carcinoma: Research has shown that dual immunotherapy achieves significant clinical efficacy, primarily because the combination of anti-PD-1 and anti-CTLA-4 increases the infiltration of effector T cells, overcoming the innate tolerance of cold CRC patients to monotherapy immunotherapy [28].